Datroway has demonstrated a median overall survival improvement of five months compared to chemotherapy as a first-line treatment for patients with metastatic triple-negative breast cancer. It has been approved in the US as a TROP2-directed antibody drug conjugate for this patient group, who are not candidates for PD-1/PD-L1 inhibitors. The approval appears to be a significant development, although the context and timing of the approval are not entirely clear.